The Pharma Top 20s

Jul 12, 2012
By Pharmaceutical Executive
The Pharma Top 20s

Next >

Top 25 US Products by Sales: Lipitor clung on to the top spot but increasingly feels the impact of generic competition.

Top 25 US Products by Sales

< Back  |  Next >

Top 20 Global Products: Biologics are increasing apace among the top product offerings, accounting for eight of the 20 biggest selling drugs.

Top 20 Global Products

< Back  |  Next >

Top 20 Global Therapeutic Classes: The surge in antidiabetics clearly reflects the consequences of lifestyle changes that are edging around the world.

Top 20 Global Therapeutic Classes

< Back  |  Next >

Top 25 Corporations by US Sales: Pfizer holds on at home despite falling Lipitor sales, but the loss of the Lipitor patent at the end of 2011 will make this lead increasingly tenuous.

Top 25 Corporations by US Sales

< Back  |  Next >

Top 25 Corporations by US Prescriptions: Increased prescribing of generics saw Watson, Amneal and Lupin Laboratories surge ahead in 2011.

Top 25 Corporations by US Prescriptions

< Back  |  Start >

Major patent expiries in 2012.

Major patent expiries in 2012